ICON Launches Electronic Informed Consent
Dublin, Ireland, 23rd April 2015 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced Firecrest eConsent, a next-generation electronic informed consent solution that incorporates key recommendations from the FDA’s recent draft guidance on informed consent.
The e-Consent solution is a component of ICON’s new informatics hub designed to enhance the engagement of patient populations in the development process. One of the critical parts to improving this engagement is improving the informed consent process.
Addressing the FDA’s recommendation for a more patient centric approach to presenting clinical trial information, ICON’s Firecrest eConsent employs videos and visual aids to assist in the explanation of complex scientific concepts and medical terms found in trial protocols. These educational techniques were developed based on research by Carnegie Mellon University, and have been systematically tested, to facilitate optimal patient comprehension and information retention. Firecrest eConsent enables patients to access materials via portals or through other online channels provided by the sponsor, giving patients more time to independently review and prepare questions for the physician before subsequently consenting to participate in the trial.
Conforming with the FDA’s requirement for validating that e-signatures are written by the actual patient, Firecrest eConsent uses a new proprietary method to capture, confirm, encrypt, and store biometrics for each patient’s signature.
Firecrest eConsent has also been designed to be compatible with sites’ existing IT infrastructure, enabling sites to adopt the Firecrest eConsent solution quickly and efficiently.
“Electronic informed consent helps address one of the leading causes of regulatory findings – errors in the consent process – in current paper-based processes,” commented Frances Abeton, Vice President, Firecrest. “Firecrest eConsent simplifies and provides transparency in the entire patient consent process. It thoroughly and consistently explains the trial, which instils trust in the patient, and it also offers sponsors a secure and easy-to-implement solution to drive patient enrolment and reduce the opportunities for protocol violations.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
